XML 31 R11.htm IDEA: XBRL DOCUMENT
v3.3.1.900

Operations | 12 Months Ended
--- | ---
Dec. 31, 2015
Operations [Abstract] |
Operations | Note 2 – Operations The Company’s vaccine candidates currently under development, some of which include adjuvants, will require significant additional research and development efforts that include extensive preclinical studies and clinical testing, and regulatory approval prior to commercial use. As a clinical-stage vaccine company, the Company has primarily funded its operations from proceeds through the sale of its common stock in equity offerings, convertible debt issuance (in 2016) and revenue under its contract with the Department of Health and Human Services, Biomedical Advanced Research and Development Authority (“HHS BARDA”) and, to a lesser degree, revenue under its prior contract with PATH Vaccine Solutions (“PATH”) and the grant agreement with the Bill & Melinda Gates Foundation (“BMGF”). Management regularly reviews the Company’s cash and cash equivalents and marketable securities relative to its operating budget and forecast to monitor the sufficiency of the Company’s working capital, and anticipates continuing to draw upon available sources of capital to support its product development activities.

X
- Definition Operations [Abstract] + References No definition available. + Details
Name: | nvax_OperationsAbstract
Namespace Prefix: | nvax_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for operations. + References No definition available. + Details
Name: | nvax_OperationsDisclosureTextBlock
Namespace Prefix: | nvax_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration